Releases
See all
Releases
31. May, 2021
Last subject dosed in bioavailability trial 0204 of lead product candidate
Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports...
Releases
14. May, 2021
Cessatech A/S is awarded IPO of the year 2020 by independent editorial Affärsvärlden
Among the 26 micro-companies, the IPO guide’s reviewers found an average of 2.9 flags....
Releases
19. April, 2021
First quarter report Q1-2021 – ‘one down, two to go’ of the major milestones of 2021
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1...
Releases
24. March, 2021
Cessatech reports first subject dosed in bioavailability trial of lead product candidate
Clinical trial 0204 in healthy volunteers will investigate the absolute bioavailability of CT001. Primary...
Releases
9. March, 2021
Cessatech A/S is awarded Best Medical Treatment IPO Nordics in 2020 by independent editorial
CFI.co – a journal and online resource reporting on business, economics and finance –...
Facts about Children
See all
Facts
2. February, 2021
Ny forskning: Barn bör få smärtlindring vid vaccinationer och injektioner
Barn mår bra av smärtlindring vid vanliga vaccinationer och injektioner. Det säger den senaste...
Facts
8. September, 2020
Behov for større sikkerhed omkring medicin til børn og unge i Danmark
Kun 30% af markedsførte lægemidler i EU er godkendt til børn, og kun 50%...
Facts
31. August, 2020
DR.dk focus – Børn og ældre får medicin, der ikke er godkendt til dem
Kan give voldsomme bivirkninger, når børn og ældre får medicin, der ikke er godkendt til dem...
Facts
5. June, 2020
High off-label use in Children
Studies are still needed to determine the safety and efficacy of drugs that lack FDA labeling for this vulnerable patient population. Drugs were administered off-label...
Facts
1. May, 2020
Children are not small adults
Children differ pharmacokinetically from adults, and medication for adults cannot simply be administered in smaller doses
Experience
Proven track-record within drug development and product launches, in Europe, US and Asia.
The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.
Team
Lead Asset
CT001 – Nasal spray
Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.
See details
Stay up to date!
Subscribe and get notified on Cessatech's latest news.